bcl-2 Expression and Survival in Melanoma
Author Information
Author(s): Marília B Espíndola, Oly C Corleta
Primary Institution: Universidade Federal do Rio Grande do Sul
Hypothesis
The study aimed to evaluate the relationship between bcl-2 expression in melanoma metastases and patient survival.
Conclusion
bcl-2 expression in metastases is not a reliable prognostic marker for cutaneous melanoma.
Supporting Evidence
- The study analyzed 80 slides from 50 patients diagnosed with stage III and IV melanoma.
- Mean overall survival was 33.9 months after the diagnosis of the initial metastatic lesion.
- No correlation was found between bcl-2 expression and overall survival.
Takeaway
The study looked at a protein called bcl-2 in melanoma patients and found that it doesn't help predict how long patients will live after their cancer spreads.
Methodology
A historical cohort study analyzing bcl-2 expression in surgical specimens from melanoma patients and correlating it with survival.
Potential Biases
Potential biases due to the retrospective nature of the study and incomplete patient records.
Limitations
The study had a small sample size and was retrospective, which may limit the generalizability of the findings.
Participant Demographics
50 patients, 28 male (56%) and 22 female (44%), mean age 43 years.
Statistical Information
P-Value
p=0.510
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website